Human Anti-Als3p Antibodies Are Surrogate Markers of NDV-3A Vaccine Efficacy Against Recurrent Vulvovaginal Candidiasis

Human Anti-Als3p Antibodies Are Surrogate Markers of NDV-3A Vaccine Efficacy Against Recurrent Vulvovaginal Candidiasis

A Phase 1b/2a clinical trial of NDV-3A vaccine containing a Candida albicans recombinant Als3 protein formulated with alum protected women <40 years old from recurrent vulvovaginal candidiasis (RVVC). We investigated the potential use of anti-Als3p sera as surrogate marker of NDV-3A efficacy....

Full description

Bibliographic Details
Main Authors: Priya Uppuluri, Shakti Singh, Abdullah Alqarihi, Clint S. Schmidt, John P. Hennessey, Michael R. Yeaman, Scott G. Filler, John E. Edwards, Ashraf S. Ibrahim
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-06-01
Series:Frontiers in Immunology
Subjects:
Candida albicans, RVVC
Als3p
vaccine
virulence
NDV-3
NDV-3A
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2018.01349/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2018.01349/full

Similar Items